Malaria vaccines are therapeutics that offer protection against mosquito-borne infectious disease called malaria
A vaccine for the prevention of
malaria is known as a malaria vaccine. RTS,S, also known as Mosquirix, is the
only malaria vaccine that has received official approval. By April 2022, 1
million kids who live in places where malaria transmission is moderate to high
had received the vaccine. At least three doses are needed in infants by the age
of 2, and a fourth dose prolongs the duration of protection for an additional
one to two years. Hospital admissions for severe malaria are reduced by the
vaccine by about 30%.
Malaria
vaccines are therapeutics that provide defence against the infectious
disease called malaria that is spread by mosquitoes. A parasite that frequently
infects a particular species of mosquito that feeds on humans can result in the
serious and occasionally fatal disease known as malaria. Malaria typically
causes severe illness in its victims, including high fevers, shivering chills,
and flu-like symptoms. Malaria can be fatal, but most cases of illness and
death from malaria can be avoided.
With funding from the Bill and
Melinda Gates Foundation, the PATH Malaria
Vaccines Initiative (MVI) and GlaxoSmithKline (GSK) developed RTS,S. It
is a recombinant vaccine made up of pre-erythrocytic P. falciparum
circumsporozoite protein (CSP). In addition to producing antibodies that can
stop hepatocyte invasion, the CSP antigen triggers a cellular response that
allows the hepatocytes to be infected to be destroyed. Due to the CSP vaccine's
poor immunogenicity, issues were encountered during the trial stage. By
combining the protein with a hepatitis B surface antigen to produce a more
potent and immunogenic vaccine, RTS,S attempted to avoid these problems.
Comments
Post a Comment